A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of next-generation cell and gene therapies known as CAR immune cell therapies, ...
SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support ...
James Miskin brings 25 years of cell and gene therapy experience to an advisory role focused on further unlocking ViroCell’s potential LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell ...
The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...
Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...
Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in ...
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Plasmid DNA and Viral Vector Manufacturing Services With over 20 years of plasmid DNA and viral vector ...
Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and analytical strategies must evolve together. In this joint webinar, Minaris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results